Swedish Orphan Biovitrum AB has published its 2025 Annual and Sustainability Report, highlighting the company’s achievements in advancing innovative therapies for people living with rare diseases.
Sobi continues to prioritize sustainable growth through collaboration and scientific expertise, ensuring that approved treatments are accessible to all eligible patients within its therapeutic areas. In 2025, more than 53,000 full-time equivalent patients received treatment with a Sobi medicine, supporting the company’s mission to improve the lives of individuals with rare conditions. Revenue for the year reached SEK 28 billion, representing a 15% increase at constant exchange rates (CER), while Sobi further strengthened its pipeline with therapies that have the potential to redefine the standard of care in multiple rare and severe diseases.
The report features the audited Annual Report alongside Sobi’s statutory Sustainability Report, prepared in line with the Swedish Annual Accounts Act and European Sustainability Reporting Standards (ESRS). It also includes disclosures under the Task Force on Climate-related Financial Disclosures (TCFD) and EU Taxonomy regulations.
Sobi’s 2025 Sustainability Statement reflects its alignment with the Corporate Sustainability Reporting Directive (CSRD) and the ESRS framework, with the report’s structure and content tailored to meet updated sustainability reporting standards.
The full 2025 Annual and Sustainability Report can be accessed at sobi.com. The Swedish Annual Report is also available in European Single Electronic Format (ESEF), which will take precedence in case of any discrepancies.
Click here to contact the Sobi Investor Relations Team
]]>
